What this pack is
Advil is the brand name in this record; ibuprofen is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
AdvilGeneric nameibuprofen
How this medicine works
The current label places ibuprofen in the NSAID class. That context helps explain why pain, inflammation, gastrointestinal, cardiovascular and kidney risks need review together; it does not determine personal suitability, tablet count, interval or duration.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Advil
- Generic name
- ibuprofen
- Dosage-form class
- Oral coated tablets: ibuprofen 200 mg per tablet; this dossier displays the 24-tablet bottle, NDC 0573-0150-20
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v38; effective 12 Mar 2026 and published 16 Mar 2026
200 mg per tablet; 24-tablet bottle
- Product code
- NDC 0573-0150-20
- Form and route
- coated tablet · oral
- Container
- 24-tablet bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-19; actual marketing, stock and availability are not established.
- ibuprofen
- 200 mglabelled amount per tablet/caplet; not an individual's tablet count
- Package
- 24 tablets per bottle
- Labelled appearance
- pinkish brown · 11 mm round tablet · imprint AdvilUnscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ADVIL label reading: 200 mg first identifies the exact coated tablet, then check duplicate NSAIDs
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module only helps check the exact Advil coated tablet, ibuprofen per tablet, package and Drug Facts risks; it provides no personal tablet count, interval, duration, missed-use, stopping or substitution plan.
- Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). Check aspirin, naproxen, ibuprofen and other pain, cold or prescription medicines for class or ingredient overlap; different brands do not permit self-combination.
- The label warns about stomach bleeding, especially for people aged 60 or older, with ulcer or bleeding history, or using anticoagulants, steroids, other NSAIDs or more alcohol. Black stools, vomiting blood, persistent stomach pain or fainting warrants timely local medical support.
- Kidney disease, diuretics, multiple cardiovascular medicines or dehydration require clinician or pharmacist review of the complete medicine list; this page provides no supposed safe kidney threshold or personal plan.
- NSAID use at 20 weeks of pregnancy or later requires discussion with a professional using the current label and FDA safety information. This page does not decide suitability from gestational age.
- If low-dose aspirin is used for prevention, do not stop, space or replace it from a webpage; have a clinician or pharmacist review aspirin, ibuprofen, naproxen and every medicine pack together.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ADVIL ibuprofen public label (Haleon; SPL v38) ↗reviewed 2026-08-20
Reviewed official safety records
A dated record is not automatically a current alert. Read the named product, form, batch, market, date and source type before treating it as relevant.
- FDA Drug Safety Communication: NSAID risk communication in pregnancy at about 20 weeks or later, including ibuprofen2020-10-15 · On 2020-10-15, FDA issued an NSAID Drug Safety Communication that explicitly names ibuprofen and says the risk communication applies to prescription and over-the-counter NSAIDs: use at about 20 weeks of pregnancy or later may be associated with fetal kidney problems and low amniotic fluid. The Advil dossier links this dated U.S. class communication through ibuprofen as its active-ingredient clue. It does not mean that any Advil pack, another ibuprofen product, another market or any individual has a problem, and it does not support self-starting, stopping, switching, changing an amount or replacing pain medicine. Pregnancy, suspected pregnancy, pain or fever questions require review of the exact product, current target-market label and complete medicine list with the prescribing team or pharmacist.Primary-source record (open linked document) ↗reviewed 2026-08-22
Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Advil (ibuprofen). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Advil is the brand in this record and ibuprofen is the active-ingredient name. Check both with the dosage form (Oral coated tablets: ibuprofen 200 mg per tablet; this dossier displays the 24-tablet bottle, NDC 0573-0150-20) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When COUMADIN / warfarin is on the same list: an anticoagulant is a priority review cue
The current U.S. public Drug Facts for ADVIL lists use of a blood-thinning anticoagulant as a risk cue in its stomach-bleeding warning. This card only signals that the actual Advil pack, warfarin pack, other pain/cold products, prescription medicines, OTC products and supplements need review by the responsible team; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Coumadin / warfarin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗reviewed 2026-08-20HOW IT WORKS · NOT A TREATMENT PLAN
How ibuprofen works: an NSAID class explanation is not an individual regimen
- A shared NSAID class or 200 mg marking does not make another ibuprofen, naproxen, aspirin or combination product self-combinable or substitutable.
- Coated tablets, caplets, Liqui-Gels, children's liquids and topical products are different product identities and cannot be collapsed by brand or generic name alone.
- Chest pain, breathing difficulty, sudden weakness, serious gastrointestinal bleeding signs, markedly reduced urine or acute allergy warrants local urgent medical support.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
SOURCE-TRACEABLE ARCHIVE
Advilibuprofen
This page includes an exact current U.S. public-label package panel for Advil, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
U.S. marketing start node listed in the current label
This node supports U.S. product history for NDA 018989 and does not establish another market or another Advil-family product.
DailyMed: current ADVIL public label, SPL v38 ↗SPL v38 effective and publication dates
The current label became effective 12 Mar 2026 and was published 16 Mar 2026; this dossier displays only the 24-tablet round coated-tablet bottle, NDC 0573-0150-20.
DailyMed: current ADVIL public label, SPL v38 ↗
MARKET SCOPE
Market-record boundary
United States
Current NDA 018989 label and one exact package linkedSPL v38 and NDC 0573-0150-20 were reviewed through 19 Aug 2026; this does not establish actual marketing, stock or availability.
Other Advil products and other markets
Explicitly separate or not establishedLiqui-Gels, caplets, PM, Dual Action, children's liquids and other markets are not merged into this coated-tablet presentation.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Can someone using aspirin self-switch to Advil or adjust timing?
A webpage cannot decide this. Do not self-stop preventive aspirin; have a clinician or pharmacist review aspirin, ibuprofen, naproxen and the complete medicine list.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.